Elutia Inc. Share Price

Equities

ELUT

US05479K1060

Pharmaceuticals

Delayed Nasdaq 21:30:00 30/04/2024 BST 5-day change 1st Jan Change
2.77 USD -5.46% Intraday chart for Elutia Inc. -3.35% +28.24%
Sales 2024 * 26.45M 2.12B Sales 2025 * 39M 3.12B Capitalization 67.45M 5.4B
Net income 2024 * -34M -2.72B Net income 2025 * -28M -2.24B EV / Sales 2024 * 2.55 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.73 x
P/E ratio 2024 *
-1.72 x
P/E ratio 2025 *
-2.14 x
Employees 54
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.46%
1 week-3.35%
1 month-12.06%
3 months-23.27%
6 months+136.75%
Current year+28.24%
More quotes
1 week
2.75
Extreme 2.7454
2.99
1 month
2.75
Extreme 2.7454
3.20
Current year
2.16
Extreme 2.16
4.19
1 year
1.10
Extreme 1.1001
4.19
3 years
1.10
Extreme 1.1
12.92
5 years
1.10
Extreme 1.1
18.20
10 years
1.10
Extreme 1.1
18.20
More quotes
Managers TitleAgeSince
Founder 52 05/08/15
Founder 63 05/08/15
Director of Finance/CFO 56 27/09/20
Members of the board TitleAgeSince
Founder 63 05/08/15
Director/Board Member 68 31/08/20
Founder 52 05/08/15
More insiders
Date Price Change Volume
30/04/24 2.77 -5.46% 46,686
29/04/24 2.93 +5.40% 32,757
26/04/24 2.78 -3.81% 13,269
24/04/24 2.89 +0.84% 6,674
23/04/24 2.866 -1.85% 4,416

Delayed Quote Nasdaq, April 30, 2024 at 09:30 pm

More quotes
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.77 USD
Average target price
5.5 USD
Spread / Average Target
+98.56%
Consensus